Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question

Serge P. Eholié1,2,3*, Anani Badje2,3, Gérard M. Kouame3, Jean-Baptiste N’takpe3, Raoul Moh1,2,3, Christine Danel2,3 and Xavier Anglaret2,3

Abstract

After a period where it was recommended to start antiretroviral therapy (ART) early, the CD4 threshold for treating asymptomatic adults dropped to 200/mm³ at the beginning of the 2000s. This was mostly due to a great prudence with regards to drug toxicity. The ART-start CD4 threshold in most international guidelines was then raised to 350/mm³ in 2006–2009 and to 500/mm³ in 2009–2013. Between 2012 and 2015, international guidelines went the last step further and recommended treating all HIV-infected adults regardless of their CD4 count. This ultimate step was justified by the results of three randomized controlled trials, HPTN 052, Temprano ANRS 12136 and START. These three trials assessed the benefits and risks of starting ART immediately upon inclusion (“early ART”) versus deferring ART until the current starting criteria were met (“deferred ART”). Taken together, they recruited 8427 HIV-infected adults in 37 countries. The primary outcome was severe morbidity, a composite outcome that included all-cause deaths, AIDS diseases, and non-AIDS cancers in the three trials. The trial results were mutually consistent and reinforcing. The overall risk of severe morbidity was significantly 44–57% lower in patients randomized to early ART as compared to deferred ART. Early ART also decreased the risk of AIDS, tuberculosis, invasive bacterial diseases and Kaposi’s sarcoma considered separately. The incidence of severe morbidity was 3.2 and 3.5 times as high in HPTN052 and Temprano as in START, respectively. This difference is mostly due to the geographical context of morbidity. The evidence is now strong that initiating ART at high CD4 counts entails individual benefits worldwide, and that this is all the more true in low resource contexts where tuberculosis and other bacterial diseases are highly prevalent. These benefits in addition to population benefits consisting of preventing HIV transmission demonstrated in HPTN052, justify the recommendation that HIV-infected persons should initiate ART regardless of CD4 count. This recommendation faces many challenges, including the fact that switching from “treat at 500 CD4/mm³” to “treat everyone” not only requires more tests and more drugs, but also more people to support patients and help them remain in care.

Keywords: Early antiretroviral treatment, Randomized controlled trial

Background

The optimal threshold for initiating ART: a 20-year quest

1981–1996: The no-treatment era

During the first 15 years of the HIV pandemic, no treatment could sustainably control the replication of the virus and decrease mortality in HIV-infected people. The main direct and indirect consequence of the virus activity was infected and uninfected CD4 + T cells (CD4) death, causing progressively worsening immunosuppression, which exposed patients to the growing risk of opportunistic infection and death. The degree of immunosuppression and the subsequent risk of death over time were estimated with the CD4 count and with a clinical stage, as determined based on the opportunistic diseases that occurred in the patient. These two elements, CD4 count and clinical stage, enabled the setting of thresholds for some therapeutic decisions such as the initiation of
prophylaxis for the major opportunistic infections. This notion of “threshold” is crucial: it influenced the administration of anti-HIV treatments for almost 30 years.

1996: The sudden arrival of a highly potent treatment
In the mid-1990s, the arrival of combined antiretroviral therapy (ART) revolutionizes the disease prognosis [1, 2]. This era is characterized by a combination of three factors: the evidence that combination therapy has a much more potent and durable effect than monotherapy, the introduction of protease inhibitors, and the capacity to measure plasma viral load using the new molecular amplification techniques. By controlling viral replication, combination ART prevents cell death, increases CD4 count and restore immunity. This results in a dramatic decline in the risk of opportunistic infection and death [3]. In the first years of combination ART, “hit hard, hit early” becomes the mantra, with the hope that exerting maximal antiviral pressure on the virus during the initial phase of infection will prevent virus mutations and favour treatment success [4].

Combination ART controls the virus, however, it does not eradicate it. HIV reservoirs are shown to persist, even if plasma viremia is successfully suppressed for prolonged periods of time [5, 6]. From a fatal untreatable disease, HIV infection thus becomes a chronic disease requiring lifelong treatment. Like any chronic therapy, ART involves adherence issues and carries risks of cumulative toxicity; and like any anti-infective therapy, it carries risks of emergence of resistance, especially if it is not taken properly. To spare the patient unnecessary risks of toxicity and resistance, ART should therefore not be initiated “too early”—i.e. at an immuno-clinical stage where the treatment risks would outweigh the disease risks. This is where the quest for the “optimal immuno-clinical threshold for initiating ART” begins.

1996–2014: Looking for the golden CD4 threshold
“When to start ART?” is essentially a risk/benefit question, but knowledge on benefits and risks changes over time. During the first 10 years of ART, the ART-start threshold fluctuates. After a short period in the late 1990s where it is recommended to start treatment from 500 CD4/mm³ without randomized trial evidence, threshold for treating asymptomatic adults drops to 200/mm³ at the beginning of the 2000s (Fig. 1) [7]. This shift is mostly due to a great prudence with regards to drug toxicity, especially cardiovascular or cerebrovascular, metabolic and renal. This is the time when, in order to spare toxicity, researchers carry out randomized trials of structured treatment interruption (STI), in which ART-treated patients whose CD4 count rises above 350/mm³ are proposed to temporarily interrupt their treatment [8, 9]. The underlying assumptions are that ART is the main determinant of all the non-HIV adverse effects and illness being observed in the early era of combination ART,

Fig. 1 Temporal evolution of CD4 criteria to initiate ART in asymptomatic HIV+ adults (IAS, DHHS, EACS and WHO Guidelines) [1]. (1) Adapted from Marco Antonio Vitoria, WHO, Geneva. cART combined antiretroviral therapy. DHHS U.S. Department of Health and Human Services. EACS European AIDS Clinical Society. IAS International AIDS Society. WHO World Health Organisation.
and that ART’s primary goal is to maintain CD4 above 200/mm\(^3\). Therefore, any drug exposure beyond this target potentially entails unnecessary side effects.

In 2006, the results of the STI trials annihiliate this approach. Contrary to the pre-trial hypotheses, the Trivacan and SMART trials show that patients who temporarily interrupt ART at the threshold of 350 CD4/mm\(^3\) have higher risk of severe morbidity compared to those who do not interrupt ART at the same threshold \([8, 9]\). In other words, below 350/mm\(^3\), HIV disease itself is more toxic than antiretroviral drugs. Furthermore, STI trial results no only suggest that people should worry more about starting ART earlier than about interrupting it. They shed important light on HIV morbidity, make us focus back on the virus, and illustrate the importance of the context.

In STI trials conducted in high resource countries, a significant part of the extra morbidity related to treatment interruptions is made up of non-infectious diseases—non-AIDS cancers, cardiovascular and renal diseases, and interruptions leads to a rise in inflammation markers \([10, 11]\). After more than 20 years of focusing on AIDS-defining opportunistic diseases (mostly infectious) at low CD4 counts, the focus thus becomes on non-AIDS HIV-related diseases (mostly non-infectious) at high CD4 counts. Part of these diseases being likely due to viral replication, rather than to immune suppression, the question is not whether the ART-start threshold will continue to rise anymore, but how high it will get.

In STI trials conducted in low resource countries, however, most of the extra morbidity related to treatment interruptions is made up of tuberculosis and invasive bacterial diseases \([8, 12]\). These infectious diseases are more frequent in poor settings than in rich settings. They are community diseases, but also act as opportunistic diseases, meaning that they are more frequent in HIV-infected individuals than in HIV-non infected ones. Thus, it is not that surprising that the overall risk of severe morbidity in HIV-infected patients at any CD4 count is higher in low resource settings as compared to high resource ones. Therefore, at the end of the 2000s, if the case for raising the ART-start threshold is already strong worldwide because of HIV non-AIDS non-infectious diseases, it is even stronger in regions where tuberculosis and bacterial diseases are more prevalent.

From there onwards the trend toward earlier initiation of ART is unstoppable. Two multicohort studies from industrialized countries suggest that 350/mm\(^3\) should be the minimum threshold for initiation of antiretroviral therapy \([13, 14]\). A randomized trial carried out in Haiti demonstrates that starting ART immediately in patients enrolled with less than 350 CD4/mm\(^3\) decreases the rates of death and incident tuberculosis compared to starting ART at 200 CD4/mm\(^3\) \([15]\). Between 2006 and 2009 the ART-start threshold is raised to 350/mm\(^3\) worldwide. Between 2009 and 2013, most guidelines further set the threshold to 500/mm\(^3\), the shift being quicker—with some exceptions—in high resource countries than in low resource ones. Raising the CD4 threshold to 500/mm\(^3\) is based on high-quality evidence from HPTN052 that ART reduces HIV transmission, but low-quality evidence from cohort studies that ART reduces mortality or progression to AIDS \([16]\).

Finally, between 2012 and 2015, all international guidelines take the last step and recommend treating all HIV-infected adults regardless of their CD4 count \([17–20]\). This ultimate step is either corroborated or directly inspired by the results of three randomized controlled trials, HPTN 052, Temprano ANRS 12136 and START \([21–24]\).

**HPTN 052, Temprano ANRS 12136 and START: the three early ART trials**

HPTN 052, Temprano and START were three open label randomized controlled trials. They took place between 2007 and 2015. Taken together, they recruited a total 8427 HIV-infected adults in 37 countries, including 48 % in Africa, 37 % in Europe, US, Australia or Israel, 17 % in Latin America, and 10 % in Asia (Table 1; Fig. 2).

The three trials had the same primary objective, that is to assess the benefits and risks of starting ART immediately upon inclusion (“early ART”) versus deferring ART initiation until the current institutional starting criteria were met (“deferred ART”). The primary outcome was severe morbidity, a composite outcome that included all-cause deaths, AIDS diseases, and non-AIDS cancers in the three trials. In addition to these three components, the primary outcome also included: severe bacterial diseases in Temprano and HPTN052; serious cardiovascular diseases in START and HPTN052; diabetes mellitus in HPTN052; and renal or liver failure in START. HPTN052 had a co-primary endpoint, HIV transmission to the partner, and was primarily powered to interrogate HIV transmission.

Asymptomatic patients were eligible for the trial if they had CD4 counts between 350 and 550/mm\(^3\) in HPTN052, between 250 and 800/mm\(^3\) in Temprano, and higher than 500/mm\(^3\) in START. As a consequence, the median CD4 count at baseline was 436/mm\(^3\) in HPTN052, 463/mm\(^3\) in Temprano and 651/mm\(^3\) in START, and the highest CD4 count at baseline was 550/mm\(^3\) in HPTN052, 1456/mm\(^3\) in Temprano and 2296/mm\(^3\) in START. In Temprano, 41 % of participants had more than 500 CD4/mm\(^3\) at baseline.

During the trial, asymptomatic patients randomized into the deferred ART strategy started ART at 250/mm\(^3\)
### Table 1 Main characteristics of the three early ART randomized controlled trials (HPTN052, Temprano ANRS 12136, START)

|                      | HPTN052               | Temprano               | START                  |
|----------------------|-----------------------|------------------------|------------------------|
| First enrolment–last visit | June 2007–May 2011    | March 2008–Jan 2015    | April 2009–May 2015    |
| Protocol             | Open label RCT        | Open label RCT         | Open label RCT         |
| Study design         | CD4 inclusion criterion | 350 < CD4 < 550        | 250/350 < CD4 < 800<sup>a</sup> |
| ART initiation CD4 threshold<sup>b</sup> | 250                  | 200–350–500<sup>b</sup> | 350                    |
| Composite primary outcome | Death, WHO stage 4, non-AIDS cancers, tuberculosis, severe bacterial infections, serious cardiovascular, diabetes mellitus | Death, AIDS, non AIDS cancers severe bacterial infections | Death, AIDS<sup>c</sup>, non AIDS cancer, serious cardiovascular<sup>d</sup>, renal failure, liver failure |
| Number of participants | Enrolled/analyzed | 1763/1761              | 2076/2056              | 4588/4585            |
| Early ART            | 886                   | 1033                   | 2326                   |
| Deferred ART         | 875                   | 1023                   | 2359                   |
| Geographical origin  | Africa                | 54 %                   | 100 %                  | 21 %                 |
|                      | Europe, USA, Australia, Israel | –                      | –                      | 46 %                 |
|                      | Asia                  | 30 %                   | –                      | 7 %                  |
|                      | Latin America         | 16 %                   | –                      | 25 %                 |
| Baseline characteristics | % of women          | 49 %                   | 79 %                   | 27 %                 |
|                      | Age, median (IQR)     | 33 (27–39)             | 35 (29–42)             | 36 (29–44)           |
|                      | CD4 count, median (IQR; Max) | 436 (364–522; 550)     | 463 (366–572; 1456<sup>e</sup>) | 651 (584–765; 2296) |
|                      | Positive serum HBs Ag | 5 %                    | 9%                     | NA                   |
| Follow-up characteristics | Received IPT during trial follow-up, % | 3 %                    | 45 %                   | NA                   |
|                      | Follow-up, year, median (IQR) | 2.1 (1.5–2.9)         | 2.5 (2.5–2.5)         | 2.8 (2.1–3.9)       |

<sup>a</sup> RCT randomized controlled trial; IPT isoniazid prophylaxis for tuberculosis  
<sup>b</sup> ART-start CD4 threshold for asymptomatic patients randomized to the deferred ART strategy  
<sup>c</sup>  For ethical reasons, the Temprano investigators considered that the WHO revised guidelines had to be followed as soon as they were released  
Therefore, they adopted the WHO 2010 guidelines in December 2009 as soon as the WHO rapid advice was released; and further adopted the WHO 2013 guidelines in August 2013. The 2010 and 2013 guidelines revisions impacted the trial procedures at two levels: the eligibility criterion ‘no WHO criteria for starting ART’; and the criteria for starting ART in participants assigned to the Deferred-ART strategy: Asymptomatic patients were considered having ‘no WHO criteria for starting ART’ and therefore eligible for the trial: between the trial start and November 2009: if they had more than 250 CD4/mm<sup>3</sup>; Between December 2009 and July 2012: if they had more than 350 CD4/mm<sup>3</sup>; As enrolment was completed in July 2012, the WHO 2013 guidelines revision did not impact the eligibility criteria  
Asymptomatic participants assigned to the Deferred-ART strategy started ART: between the trial start and November 2009: whenever they met the WHO 2006 criteria for starting ART (CD4 count <200/mm<sup>3</sup>); Between December 2009 and July 2013: whenever they met the WHO 2010 criteria for starting ART (CD4 count <350/mm<sup>3</sup>); Between August 1st 2013: whenever they met the WHO 2013 criteria for starting ART (CD4 count <500/mm<sup>3</sup>, or stable partnership with an HIV-negative individual)  
<sup>d</sup> Excluding HSV and oesophageal candidiasis  
<sup>e</sup> Myocardial infarction, stroke, or coronary revascularization  
Temprano, patients were eligible for the trial if the pre-inclusion CD4 count (measured within 1 months prior to randomization) was below 800/mm<sup>3</sup>. The “baseline” CD4 count distribution shown here is the distribution of values measured at inclusion (i.e. after informed consent), not the pre-inclusion value that determined eligibility. This explains why some patients had CD4 counts higher than 800/mm<sup>3</sup> at baseline.
in HPTN052 and 350/mm$^3$ in START. In Temprano, the ART-start threshold was adjusted upward over time according to WHO guidelines updates, from 200/mm$^3$ in 2008–2009 to 350/mm$^3$ in 2009–2013 and 500/mm$^3$ in 2013–2015. The median follow-up in the trials varied from 2.1 to 2.8 years.
The three trials had notable differences in terms of prevention and documentation of tuberculosis. Firstly, Temprano was a factorial $2 \times 2$ trial assessing in parallel two questions: early ART, and early INH preventive therapy (IPT). Therefore, participants were randomized not only to early or deferred ART, but also to start or not a 6-month course of IPT after 1 month of follow-up, provided they had no signs or symptoms evocative of tuberculosis. As a consequence, 45 % of participants in Temprano received IPT, versus only 3 % in HPTN052 and an unknown number in START. Secondly, in Temprano and HPTN052 all cases of confirmed and probable tuberculosis were documented and included in the primary outcome, while in START only confirmed cases with positive cultures were retained. The main results of the three trials were mutually consistent and reinforcing in terms of relative risks, while showing geographical context-specific absolute risks (Table 2).

In terms of absolute risks, the incidence of severe morbidity in the deferred ART strategy was 3.2 and 3.5 as high in HPTN052 and Temprano compared to START, respectively. This difference is likely explained by the context (more patients in low resource settings in HPTN052 and Temprano), the population (higher baseline CD4 count in SMART), and the differences in the documentation of tuberculosis discussed above.

In terms of relative risks, the overall risk of severe morbidity was 44–57 % lower in patients randomized to the early ART strategy as compared to those randomized to the deferred ART strategy in Temprano and START, respectively. In Temprano, the reduction in severe morbidity was of similar magnitude and remained significant when restricting the analysis to patients who had more than 500 CD4/mm$^3$ at baseline. In HPTN052, the overall difference did not reach significance.

When considering separately each component of the composite primary outcome or important secondary outcomes, early ART significantly decreased the risk of: AIDS in the three trials; tuberculosis considered separately in the three trials; invasive bacterial diseases in Temprano and SMART; and Kaposi’s sarcoma in SMART. These are secondary analysis whose power may be limited by the number of events in each group. As shown in Table 2, the number of AIDS or non-AIDS HIV-related events was lower with early ART than in deferred ART in almost every subgroup, even if this difference did not always reach significance. Of note, in Temprano, the trial who assessed in parallel the efficacy of early ART and IPT, IPT also reduced the risk tuberculosis by 66 % overall, 68 % in patients who had less than 500 CD4/mm$^3$ at baseline and 63 % in those who had more than 500 CD4/mm$^3$ at baseline. The efficacy of ART and IPT in reducing tuberculosis was independent [22].

Finally, in the three trials, ART appeared to be equally well tolerated in both strategies (data not shown).

**Discussion**

These three trials were conducted in different geographical contexts and in populations at various immunosuppression stages. This diversity strengthens their common conclusion: all over the world, HIV-infected persons should be recommended to initiate ART regardless of CD4 count. ART initiation should not be triggered by any clinical or immunological threshold anymore, and the objective of ART clearly becomes to suppress viral replication and prevent—rather than cure—inflammation and immune deficiency.

Broadening treatment eligibility directly leads to increase the number of individuals treated. Switching from treating at 500 CD4/mm$^3$ to treating all HIV-infected persons irrespective of CD4 count meets many barriers and challenges, especially in low resource settings. Of the 35 million people living with HIV, about 19 million do not even know that they are HIV-positive [25]. The majority of those who know their status still present to care late with low CD4 counts [26]. We need a robust testing agenda, including innovative approaches such as community-based testing and self-testing to encourage early testing [27]. Furthermore, testing and initiating treatment early is not worth spending energy on it if patients stop treatment afterwards. Therefore, initiating ART irrespective of CD4 count in settings with high HIV burden requires increased capacity not only in terms of tests and drugs, but also in terms of infrastructures and trained staff empowered to support patients [28]. In resource-constrained settings, a phased approach to implementation may be needed [29, 30].

Finally, the randomized trials have shown that the benefits/risk ratio of starting ART irrespective of CD4 count is favorable. However, if ART at any CD4 count is proven to have strong benefits globally, the question remains open of whether these benefits may outweigh the risks in subgroups of patients, such as HIV controllers [31]. Therefore, now that we have given a global answer to the question of ‘when to start ART’, we should explore to question of ‘when not to start ART immediately’ at the individual level [16]. Should these challenges be addressed, recommending initiating ART irrespective of CD4 count may bring benefits that extend beyond the individual benefits demonstrated in HPTN 052, Temprano and START. A person who starts treatment earlier is less exposed to the initial complications of the treatment such as immune constitution inflammatory syndrome (IRIS), and thus easier to manage. In addition, not having to wait for a CD4 count result to decide whether to initiate ART should facilitate and shorten
the pre-treatment period. These two advantages should accelerate task delegation and help decentralize care, thus increasing the likelihood that the UNAIDS target of 90% of all people with diagnosed HIV infection receiving sustained ART will be reached by 2020 [32]. In addition, ART does not just reduce morbidity in the treated individuals, it also reduces the number of people with a detectable viral load. It thus contributes to reducing HIV transmission and to controlling the HIV epidemic [24].

### Table 2 Main outcomes of the three early ART randomized controlled trials (HPTN052, Temprano ANRS 12136, START)

|                          | Deferred ART | Early ART | Adjusted hazard ratio of Deferred vs Early ART (95% CI) |
|--------------------------|--------------|-----------|--------------------------------------------------------|
| **Composite primary outcome** |              |           |                                                       |
| HPTN052                  | 91 (4.5)     | 71 (3.5)  | 0.73 (0.52–1.03)                                       |
| Temprano                 | 111 (4.9)    | 64 (2.8)  | 0.56 (0.41–0.76)                                       |
| Baseline CD4 < 500       | 73 (5.5)     | 41 (3.0)  | 0.56 (0.38–0.83)                                       |
| Baseline CD4 ≥ 500       | 38 (4.1)     | 23 (2.4)  | 0.56 (0.33–0.94)                                       |
| START                    | 96 (1.4)     | 42 (0.6)  | 0.43 (0.30–0.62)                                       |

| **Separated outcome** |              |           |                                                       |
| Death                  |              |           |                                                       |
| HPTN052                | 15 (NA)      | 11 (NA)   | 0.73 (0.34–1.59)                                       |
| Temprano               | 26 (1.9)     | 21 (0.8)  | 0.80 (0.45–1.40)                                       |
| START                  | 21 (0.3)     | 12 (0.2)  | 0.58 (0.28–1.17)                                       |
| AIDS                    |              |           |                                                       |
| HPTN052                | 61 (NA)      | 40 (NA)   | 0.64 (0.43–0.96)                                       |
| Temprano               | 65 (2.8)     | 33 (1.4)  | 0.50 (0.33–0.76)                                       |
| START                  | 50 (0.7)     | 14 (0.2)  | 0.28 (0.15–0.50)                                       |
| Tuberculosis**          |              |           |                                                       |
| HPTN052                | 34 (1.8)     | 17 (0.8)  | 0.49 (0.28–0.89)                                       |
| Temprano               | 55 (2.4)     | 28 (1.2)  | 0.50 (0.32–0.79)                                       |
| START                  | 20 (0.3)     | 6 (0.1)   | 0.29 (0.12–0.73)                                       |
| AIDS and non-AIDS malignancies** | |           |                                                       |
| HPTN052                | 7 (NA)       | 4 (NA)    | NA                                                     |
| Temprano               | 6 (NA)       | 3 (NA)    | NA                                                     |
| START                  | 39 (NA)      | 14 (NA)   | NA                                                     |
| Invasive bacterial diseases** | |           |                                                       |
| HPTN052                | 13 (NA)      | 20 (NA)   | NA                                                     |
| Temprano               | 36 (1.5)     | 14 (0.6)  | 0.39 (0.21–0.71)                                       |
| START                  | 36 (0.5)     | 14 (0.2)  | 0.38 (0.20–0.70)                                       |
| Serious cardiovascular** | |           |                                                       |
| HPTN052                | 3 (NA)       | 1 (NA)    | NA                                                     |
| Temprano               | 6 (NA)       | 3 (NA)    | NA                                                     |
| START                  | 14 (0.20)    | 12 (0.17) | 0.84 (0.39–1.81)                                       |

**N**: number of participants who had at least one such type of outcome; **ART**: antiretroviral treatment; **NA**: non available; **PY**: person-years.

**a**: Component of the composite primary outcome in the three trials

**b**: Total number of pulmonary and extra pulmonary TB episodes recorded in the three trials: HPTN052: pulmonary, n = 30 (early: 14; deferred: 16); extra-pulmonary, n = 20 (early: 3; deferred: 17); Temprano ANRS 12136: pulmonary, n = 43 (early: 19; deferred: 24); extra-pulmonary, n = 41 (early: 9; deferred: 33). START: pulmonary, n = 23 (early: 6; deferred: 17); extra-pulmonary, n = 3 (early: 0; deferred: 3).

**c**: Cervical carcinoma, Kaposi’s sarcoma, Lymphoma, Hodgkin’s, Lymphoma, non-Hodgkin’s non-AIDS cancers

**d**: Invasive bacterial diseases were a component of the composite primary outcome in Temprano and HPTN052, and a secondary outcome in START

**e**: Serious cardiovascular diseases were a component of the composite primary outcome in START and HPTN052, and a secondary outcome in Temprano

**f**: The trials analyses were adjusted for geographic regions (START) or study site (HPTN 052 and Temprano). In Temprano, Hazard Ratios were also adjusted for the IPT/no IPT treatment.
transmission and further contribute to tuberculosis control [33] and IPT should be given even to patients who start ART at high CD4 counts [22].

Conclusions
In conclusion, the evidence is now strong that initiating ART at high CD4 counts entails individual benefits, and that this is all the more true for those who live in low resource contexts. These individual benefits in addition to previously demonstrated population benefits, consisting of preventing HIV transmission to non-HIV-infected partners, fully justify the universal recommendation that HIV-infected persons should be recommended to initiate ART regardless of CD4 count. This recommendation faces many challenges, including the fact that switching from “treat at 500 CD4/mm$^3$” to “treat everyone” is not only a matter of more tests and more drugs. It also requires more people to support patients and help them remain in care once they started treatment. Over the past years, the “Test and Treat” model has evolved to “Seek, Test and Retain”. Until HIV can be eradicated, it should now be formulated this way: “Seek, test and treat every HIV infected persons, and empower staff and patients to ensure lifelong treatment continuity” [28].

Authors’ contributions
All authors helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1 Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d’Ivoire. 2 Inserm U1219, Université de Bordeaux, Bordeaux, France. 3 Programme PACC-A-NRS Research Site, Abidjan, Côte d’Ivoire.

Acknowledgements
Funding support: Thanks to the French National Agency for AIDS and viral hepatitis research (ANRS, Paris, France; Grants ANRS 12136, ANRS 12224, ANRS 12253): Brigitte Bazin, Jean François Delfraissy (director), Pauline Justumsw, Thierry Menvielle, Aurelien Mollard, Claire Rekacewicz, Marie de Solere.

Competing interests
The authors declare that they have no competing interests.

Received: 9 April 2016 Accepted: 12 July 2016

Published online: 26 July 2016

References
1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 in persons with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60.
3. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333(7):450–1.
4. Chun TW, Stuyver L, Moxel SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193–7.
5. Finzi D, Hermannova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300.
6. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288(2):22–35.
7. Daniel C, Moh R, Minga A, Arzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981–9.
8. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arundo RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2293–96.
9. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44.
10. Rodger AJ, Fox Z, Lundgren J, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200(6):973–83.
11. Dart Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS. 2008;22(2):237–47.
12. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV in N Engl J Med. 2009;360(18):1815–26.
13. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63.
14. Severe P, Juze MA, Ambrose A, Eliac LA, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257–65.
15. Ehiole SP, Vella S, Anglae X. Commentary: Antiretroviral therapy initiation criteria in low resource settings—from ‘when to start’ to ‘when not to start’. AIDS. 2014;28(Suppl 2):S101–4.
16. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://www.who.int/hiv/pub/guidelines/earlyrelav-er/en/.
17. EACS. Guidelines, Version 8.0. http://www.eacsociety.org/files/guidelines_8_0-english_webpdf.
18. OHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://www.aidsinfo.gov/contentfiles/lvguidelines/adultandadolescentglpdf.
19. International Antiviral Society-USA Panel. Antiretroviral Treatment of Adult HIV Infection. www.iasusa.org/content/antiretroviral-treatment-adult-hiv-infection-0 (2015).
20. Insight START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
21. ANRS Tempranco 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.
22. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–90.
23. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
24. UNAIDS. The gap report. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap report_2015_en.pdf.
27. WHO. Consolidated guidelines on HIV testing services. http://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/.
28. Abdool Karim SS. Overcoming impediments to global implementation of early antiretroviral therapy. N Engl J Med. 2015;373(9):875–6.
29. Vella S. End of AIDS on the horizon, but innovation needed to end HIV. Lancet HIV. 2015;2(3):e74–5.
30. Flexner C, Plumley B, Brown Ripin DH. Treatment optimization: an outline for future success. Curr Opin HIV AIDS. 2013;8(6):523–7.
31. Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013;9(10):e1003691.
32. UNAIDS. 90-90-90—An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/en/resources/documents/2014/90-90-90.
33. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9(6):446–69.